Business
    Next Score View the next score

    mass. mover

    Biogen Idec slips after stock’s rating is cut

    Weston-based Biogen Idec makes  drugs to treat neurodegenerative diseases, hemophilia, and autoimmune disorders.
    Suzanne Kreiter/Globe Staff
    Weston-based Biogen Idec makes drugs to treat neurodegenerative diseases, hemophilia, and autoimmune disorders.

    Biogen Idec Inc., maker of the multiple sclerosis drug Tecfidera, fell after Citigroup cut the stock to “neutral” from “buy.” The shares had rallied 52 percent this year through Tuesday, Bloomberg News reported. Citi’s analyst cited concerns about regulatory protections for Tecfidera in the European Union when other drug makers submit applications to make generic versions.

    Advertisement